创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

姚成, 朱盼盼, 谢东. 艾滋病抗病毒治疗及药物研究进展[J]. 药学进展, 2018, 42(2): 84-98.
引用本文: 姚成, 朱盼盼, 谢东. 艾滋病抗病毒治疗及药物研究进展[J]. 药学进展, 2018, 42(2): 84-98.
YAO Cheng, ZHU Panpan, XIE Dong. Advances in Antiretroviral Therapy and Drug Development for AIDS[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 84-98.
Citation: YAO Cheng, ZHU Panpan, XIE Dong. Advances in Antiretroviral Therapy and Drug Development for AIDS[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 84-98.

艾滋病抗病毒治疗及药物研究进展

Advances in Antiretroviral Therapy and Drug Development for AIDS

  • 摘要: 获得性免疫缺陷综合征,又称“艾滋病”,是由人免疫缺陷病毒感染引起的全球流行的传染性疾病。抗逆转录病毒治疗已经取得了显著的临床疗效,但由于不能彻底地清除人免疫缺陷病毒,长期抗病毒治疗需要面对药物的毒副作用、耐药病毒产生和传播、患者依从性差以及每日口服药物不便利性等问题。在目前无疫苗和治愈技术情况下,随着治疗人群迅速扩大、患者寿命及治疗时间显著延长,临床上对艾滋病新药、新技术有持续需求。复方单片制剂、长效注射药物、广谱中和抗体介导的免疫治疗、全新作用机制药物以及预防性疫苗,将是艾滋病防控突破目前瓶颈的关键。综述了艾滋病抗病毒治疗及相关新药的研究进展。

     

    Abstract: Acquired immune deficiency syndrome (AIDS) is a global epidemic infectious disease caused by infection of human immunodeficiency virus (HIV). Antiretroviral therapy (ART) has achieved significant clinical efficacy and success. However, due to the inability to completely eradicate HIV virus, long-term antiviral therapy may be challenged by toxic and side effects of drugs, emergence of drug-resistant viruses, poor patients' compliance, and inconvenience of daily oral administration. Since vaccines and cures are currently unavailable, there is a continuous demand for new drugs and new strategies against AIDS with the rapid expansion of treatment population as well as significant prolongation of life expectancy and treatment duration. Single-pill combinations, long-acting injectables, broadly neutralizing antibody-mediated immunotherapies, drugs with novel mechanisms of action, and preventive vaccines will play key roles in breaking the bottleneck for prevention and control of AIDS. The advances in antiretroviral therapy and drug development for AIDS have been reviewed in this paper.

     

/

返回文章
返回